UroGen Pharma Ltd. (URGN) shares outstanding
UroGen Pharma Ltd. (URGN) had 48.12M diluted shares on average in fiscal 2025 (the year ended December 31, 2025). That is 12.2% higher than the 42.88M of fiscal 2024. Figures as of 18 Nov 2026, 12:43 UTC, from the company's filings with the SEC and Yahoo Finance.
Key facts
- Shares outstanding, fiscal 2025
- 48.12M
- Change on fiscal 2024
- +12.2%
- Highest on record
- 48.12Mfiscal 2025
- Lowest on record
- 22.35Mfiscal 2021
- Fiscal years on record
- 52021–2025
Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.
UroGen Pharma Ltd. shares outstanding, in more detail
The market data feed counts 49.05M shares outstanding today.
Across the 5 fiscal years on record (2021–2025), the highest was 48.12M in fiscal 2025 and the lowest 22.35M in fiscal 2021.
Shares outstanding by fiscal year
UroGen Pharma Ltd. shares outstanding, year by year
| Fiscal year | Shares outstanding | Change | Year ended |
|---|---|---|---|
| 2025 | 48.12M | 12.2% up | |
| 2024 | 42.88M | 48.7% up | |
| 2023 | 28.83M | 26.4% up | |
| 2022 | 22.81M | 2.1% up | |
| 2021 | 22.35M | — |
Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
The share count for each fiscal year is the diluted weighted average the company reports with its earnings per share, re-based for later stock splits; the number outstanding today comes from the market data feed.
How to read it
A falling count means buybacks are giving each remaining share a larger slice of the company; a rising one means owners are being diluted.
UroGen Pharma Ltd., figure by figure
- UroGen Pharma Ltd. market cap
- UroGen Pharma Ltd. revenue
- UroGen Pharma Ltd. earnings
- UroGen Pharma Ltd. earnings per share (EPS)
- UroGen Pharma Ltd. P/E ratio
- UroGen Pharma Ltd. P/S ratio
- UroGen Pharma Ltd. P/B ratio
- UroGen Pharma Ltd. free cash flow
- UroGen Pharma Ltd. operating margin
- UroGen Pharma Ltd. dividend
- UroGen Pharma Ltd. total debt
- UroGen Pharma Ltd. cash on hand
- UroGen Pharma Ltd. total assets
- UroGen Pharma Ltd. return on equity (ROE)
- UroGen Pharma Ltd. return on invested capital (ROIC)
UroGen Pharma Ltd. (URGN) overview: price, valuation and scorecard
UroGen Pharma Ltd. shares outstanding: questions and answers
How many shares does UroGen Pharma Ltd. have?
UroGen Pharma Ltd. (URGN) had 48.12M diluted shares on average in fiscal 2025 (the year ended December 31, 2025). That is 12.2% higher than the 42.88M of fiscal 2024. The market data feed counts 49.05M shares outstanding today.
What are the highest and lowest diluted share count figures on record for UroGen Pharma Ltd.?
Across the 5 fiscal years on record (2021–2025), the highest was 48.12M in fiscal 2025 and the lowest 22.35M in fiscal 2021.
How is UroGen Pharma Ltd.'s diluted share count calculated?
The share count for each fiscal year is the diluted weighted average the company reports with its earnings per share, re-based for later stock splits; the number outstanding today comes from the market data feed. For UroGen Pharma Ltd. it is on record here for 5 fiscal years, 2021 to 2025.
Fiscal years are named for the calendar year they end in.
Learn: shares outstanding
All stocks guides →- What market capitalization is, and what it is not
Market capitalization is the share price multiplied by the number of shares outstanding: 1 billion shares at $50 is a $50 billion company. It measures the size the stock market puts on a company's equity today. It is not a sale price, it ignores debt and cash, and index providers often count only the freely traded part, the float.
- Market cap vs enterprise value: what is the difference?
Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
Cite this page
Funkfolio, “UroGen Pharma Ltd. (URGN) shares outstanding”, data as of 18 November 2026. https://funkfolio.com/stock/URGN/shares-outstanding
Underlying data: the company's filings with the SEC and Yahoo Finance.